Overview

Study Title: Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (Nepafenac Ophthalmic Suspension) 0.3% QD With Extra (Pulse) Dose on Day of Surgery for Treatment of Ocular Inflammation Associated With Cataract Surgery

Status:
Completed

Trial end date:
2019-03-01

Target enrollment:

Participant gender:

Summary

Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (nepafenac Ophthalmic Suspension) 0.3% QD with extra (pulse) dose on day of surgery for Treatment of Ocular Inflammation Associated with Cataract Surgery

Phase:

Phase 4

Details

Lead Sponsor:

Silverstein Eye Centers

Collaborators:

Bausch & Lomb Incorporated
Churchhill Communications
Statistics & Data Corporation

Treatments:

Bromfenac
Nepafenac
Ophthalmic Solutions
Pharmaceutical Solutions